The 53 percent may have come from a test done in the Congo, but it was Ebola, not COVID:
https://link.springer.com/article/10.1007/s15010-020-01557-7
The study was also terminated prematurely because of high case fatality rate of 53% in the remdesivir group compared to other competitive Ebola drugs